Immunis.AI

Immunis.AI is a biotechnology company that has developed a patented platform for cancer detection using the immune system response as a diagnostic biomarker. The company Intelligentia platform combines machine learning with disease-specific algorithms to analyze RNA expression changes triggered by the immune system rapid reaction to threats. Because the immune system amplifies its response internally, even small threats produce measurable changes in RNA expression that can be detected through blood samples. This approach enables early cancer detection by leveraging the natural amplification structure of immune responses, potentially identifying cancers before symptoms appear or imaging detects tumors. The platform is designed to develop diagnostic tests across multiple cancer types. Founded in 2012 and headquartered in Royal Oak, Michigan, Immunis.AI has raised $40 million through Series C funding from investor Savitr Capital.